These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 35803542)

  • 21. A large portion of meningococcal antigen typing system-negative meningococcal strains from spain is killed by sera from adolescents and infants immunized with 4CMenB.
    Abad R; Biolchi A; Moschioni M; Giuliani MM; Pizza M; Vázquez JA
    Clin Vaccine Immunol; 2015 Apr; 22(4):357-60. PubMed ID: 25630407
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose.
    Snape MD; Saroey P; John TM; Robinson H; Kelly S; Gossger N; Yu LM; Wang H; Toneatto D; Dull PM; Pollard AJ
    CMAJ; 2013 Oct; 185(15):E715-24. PubMed ID: 24062178
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity and Safety of Investigational MenABCWY Vaccine and of 4CMenB and MenACWY Vaccines Administered Concomitantly or Alone: a Phase 2 Randomized Study of Adolescents and Young Adults.
    Beran J; Dražan D; Enweonye I; Bhusal C; Toneatto D
    mSphere; 2021 Dec; 6(6):e0055321. PubMed ID: 34787449
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase 3 study to assess the immunogenicity, safety, and tolerability of MenB-FHbp administered as a 2-dose schedule in adolescents and young adults.
    Drazan D; Czajka H; Maguire JD; Pregaldien JL; Maansson R; O'Neill R; Anderson AS; Balmer P; Beeslaar J; Perez JL
    Vaccine; 2022 Jan; 40(2):351-358. PubMed ID: 34961633
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trial.
    Marshall HS; Richmond PC; Beeslaar J; Jiang Q; Jansen KU; Garcés-Sánchez M; Martinón-Torres F; Szenborn L; Wysocki J; Eiden J; Harris SL; Jones TR; Lee SS; Perez JL;
    Lancet Infect Dis; 2017 Jan; 17(1):58-67. PubMed ID: 27745812
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Four-component Meningococcal Serogroup B Vaccine Induces Antibodies With Bactericidal Activity Against Diverse Outbreak Strains in Adolescents.
    Biolchi A; Tomei S; Santini L; La Gaetana R; Mori E; Novy P; Rappuoli R; Bekkat-Berkani R; Giuliani MM; Pizza M
    Pediatr Infect Dis J; 2021 Feb; 40(2):e66-e71. PubMed ID: 33060520
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multicomponent meningococcal serogroup B vaccination elicits cross-reactive immunity in infants against genetically diverse serogroup C, W and Y invasive disease isolates.
    Biolchi A; De Angelis G; Moschioni M; Tomei S; Brunelli B; Giuliani M; Bambini S; Borrow R; Claus H; Gorla MCO; Hong E; Lemos APS; Lucidarme J; Taha MK; Vogel U; Comanducci M; Budroni S; Giuliani MM; Rappuoli R; Pizza M; Boucher P
    Vaccine; 2020 Nov; 38(47):7542-7550. PubMed ID: 33036804
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of anti-NHba antibody in bactericidal activity elicited by the meningococcal serogroup B vaccine, MenB-4C.
    Partridge E; Lujan E; Giuntini S; Vu DM; Granoff DM
    Vaccine; 2017 Jul; 35(33):4236-4244. PubMed ID: 28651840
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Breadth and Duration of Meningococcal Serum Bactericidal Activity in Health Care Workers and Microbiologists Immunized with the MenB-FHbp Vaccine.
    Lujan E; Partridge E; Giuntini S; Ram S; Granoff DM
    Clin Vaccine Immunol; 2017 Aug; 24(8):. PubMed ID: 28566335
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pooled-sera hSBA titres predict individual seroprotection in infants and toddlers vaccinated with 4CMenB.
    Budroni S; Kleinschmidt A; Boucher P; Medini D
    Vaccine; 2016 May; 34(23):2579-84. PubMed ID: 27083425
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension study in adolescents.
    Vesikari T; Østergaard L; Beeslaar J; Absalon J; Eiden JJ; Jansen KU; Jones TR; Harris SL; Maansson R; Munson S; O'Neill RE; York LJ; Perez JL
    Vaccine; 2019 Mar; 37(12):1710-1719. PubMed ID: 30770221
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multicomponent meningococcal serogroup B vaccine (4CMenB; Bexsero(®)): a review of its use in primary and booster vaccination.
    Carter NJ
    BioDrugs; 2013 Jun; 27(3):263-74. PubMed ID: 23575646
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cross-reactivity of 4CMenB vaccine-induced antibodies against meningococci belonging to non-B serogroups in Italy.
    Fazio C; Biolchi A; Neri A; Tomei S; Vacca P; Ambrosio L; Palmieri A; Mori E; La Gaetana R; Pizza M; Giuliani MM; Serino L; Stefanelli P
    Hum Vaccin Immunother; 2021 Jul; 17(7):2225-2231. PubMed ID: 33522380
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Methods to evaluate serogroup B meningococcal vaccines: From predictions to real-world evidence.
    Borrow R; Taha MK; Giuliani MM; Pizza M; Banzhoff A; Bekkat-Berkani R
    J Infect; 2020 Dec; 81(6):862-872. PubMed ID: 32745637
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vaccines against Neisseria meningitidis serogroup B strains - What does genomics reveal on the Portuguese strain's coverage.
    Bettencourt C; Nogueira P; Paulo Gomes J; João Simões M
    Vaccine; 2022 Aug; 40(33):4772-4779. PubMed ID: 35778280
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of strain coverage of the multicomponent meningococcal serogroup B vaccine (4CMenB) administered in infants according to different immunisation schedules.
    Biolchi A; Tomei S; Santini L; Welsch JA; Toneatto D; Gaitatzis N; Bai X; Borrow R; Giuliani MM; Mori E; Pizza M
    Hum Vaccin Immunother; 2019; 15(3):725-731. PubMed ID: 30352000
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Meningococcal Serogroup B Bivalent rLP2086 Vaccine Elicits Broad and Robust Serum Bactericidal Responses in Healthy Adolescents.
    Vesikari T; Østergaard L; Diez-Domingo J; Wysocki J; Flodmark CE; Beeslaar J; Eiden J; Jiang Q; Jansen KU; Jones TR; Harris SL; O'Neill RE; York LJ; Crowther G; Perez JL
    J Pediatric Infect Dis Soc; 2016 Jun; 5(2):152-60. PubMed ID: 26407272
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial.
    Gossger N; Snape MD; Yu LM; Finn A; Bona G; Esposito S; Principi N; Diez-Domingo J; Sokal E; Becker B; Kieninger D; Prymula R; Dull P; Ypma E; Toneatto D; Kimura A; Pollard AJ;
    JAMA; 2012 Feb; 307(6):573-82. PubMed ID: 22318278
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Persistence of the immune response after 4CMenB vaccination, and the response to an additional booster dose in infants, children, adolescents, and young adults.
    Martinón-Torres F; Nolan T; Toneatto D; Banzhoff A
    Hum Vaccin Immunother; 2019; 15(12):2940-2951. PubMed ID: 31246520
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity of a Meningococcal B Vaccine during a University Outbreak.
    Basta NE; Mahmoud AA; Wolfson J; Ploss A; Heller BL; Hanna S; Johnsen P; Izzo R; Grenfell BT; Findlow J; Bai X; Borrow R
    N Engl J Med; 2016 Jul; 375(3):220-8. PubMed ID: 27468058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.